Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

The Pathologist / App Notes / 2020 / ClearLLab 10C Panel Markers and how they are combined

ClearLLab 10C Panel Markers and how they are combined

05/05/2020

Share

 

Flow cytometric immunophenotyping remains an indispensable tool for the diagnosis, classification, staging, and monitoring of hematologic neoplasms. There have been significant advances in flow cytometry instrumentation and availability of an expanded range of antibodies and fluorochromes that have improved the ability to identify different normal cell populations and recognize phenotypic aberrancies.

 

 

ClearLLab 10C Panels consists of a set of four 10-Color reagents in dry unitized format, composed of antibodies directed against T, B, NK and Myeloid lineage antigens. These panels are designed to include the primary antibodies which are lineage oriented as per the 2006 Bethesda consensus. The combinations are intended to identify the leukocyte subpopulations that express these antigens alone or in specific co-expression patterns, and are designed to work with both normal samples and samples coming from any patient having or suspected of having the following hematopoietic neoplasms: chronic leukemia, acute leukemia, non-Hodgkin lymphoma, myeloma, myelodysplastic syndrome (MDS), and/or myeloproliferative neoplasms (MPN). The specific choices and combinations in the ClearLLab 10C Panels are based on the guiding principles of (1) addressing the clinical indications, (2) accounting for all major cell populations present in the specimen, and (3) providing sufficiently comprehensive identification of all major categories of hematopoietic cell populations in both normal and neoplastic states. (1-10) The normal cells within the sample act as an internal reference and can be used to determine whether a marker is brighter or dimmer than expected on a specific cell population. The inclusion of a backbone and redundant markers within the panels makes it easier to track populations between tubes, merge the data and troubleshoot unexpected results. In the panel the backbone of CD45 and CD34 are included in each tube. CD45 is used for consistent gating across all the four tubes. CD34 in combination with weak CD45 positivity can be used to confirm the hematopoietic origin of cells. Other redundant markers have been included in the panels such as CD13 and HLA-DR, in both M1 and M2 tubes.

 

 

>> Download the Full Application Note as a PDF

 

Newsletters

Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Related Content

OncoKDM Lite: Improving TSO500 data interpretation accuracy from VCF files in oncology routine practice

March 2, 2020

Deep Proteomic Profiling of Subregions within the Tumor Microenvironment Using Novel MALDI Guided SpatialOMx®

March 13, 2020

ClearLLab 10C Panel Markers and how they are combined

May 5, 2020

ClearLLab Control Cells - A Process Control for ClearLLab 10C Application

May 5, 2020

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.